

## **Safinamide benefits Quality of Life (QoL) during long term treatment in both Early and Advanced Parkinson's disease (PD) patients.**

Anand R<sup>1</sup>, Stocchi F<sup>2</sup>, Borgohaim R<sup>3</sup>, Schapira AH<sup>4</sup>, Bonizzoni E<sup>5</sup>, Lucini V<sup>6</sup> and Giuliani R<sup>6</sup>.

<sup>1</sup> APC AG, St Moritz, Switzerland; <sup>2</sup> Department of Neuroscience, IRCCS San Raffaele, Rome, Italy; <sup>3</sup> Nizam's Institute of Medical Sciences, Hyderabad, India; <sup>4</sup> Institute of Neurology, Queen Square, UCL, London UK; <sup>5</sup> Department of Occupational Health L. Devoto, Section of Medical Statistics and Biometry, University of Milan, Milan, Italy; <sup>6</sup> Newron Pharmaceuticals, Spa, Bresso, Italy;

**Objective:** Demonstrate the benefit of safinamide on QoL and other PD symptoms during randomized long term treatment.

**Methods:** An 18 month study (015/017) in early PD patients on single dopamine agonist, and a 24 month study (016/018) in patients with motor fluctuations on L-DOPA and other PD medications, evaluated the benefits of safinamide (50-100 mg/day) on QoL, motor symptoms and depression. These effects were studied to determine a pattern that would suggest if the benefits of safinamide on QoL were primarily due to an effect on mood or were driven by the benefits on motor symptoms.

**Results:** Both studies indicated statistically significant improvements in QoL (Euro QoL, PDQ-39). Analysis of the study in early PD patients demonstrated a statistically significant benefit in QoL for safinamide 50-100 mg/day vs placebo LS-mean diff. -0.71 (CI<sub>95%</sub> -1.23, -0.19) P=0.0079. Analysis for fluctuating patients on L-DOPA showed a similar statistical benefit in QoL (PDQ-39) for safinamide 100 mg/day vs placebo LS mean diff. -3.1 (CI<sub>95%</sub> -5.2, -1.0) p<0.05. In patients with early PD, the QoL benefits were associated with statistically significant (P<0.05) improvement in UPDRS II and III, while in advanced patients with motor fluctuations this benefit was associated with statistically significant improvement in UPDRS II and III and GRID-HAMD .

**Conclusion:** The benefit of safinamide 50-100 mg/day on QoL in both early and late PD patients appears to result from its long term benefits on motor symptoms and ADL. In patients with motor fluctuations, there was also an accompanying benefit on mood symptoms.

**Keywords:** (Five allowed [max 250 characters]): Parkinson's disease, safinamide, quality of life, depression, motor symptoms.

**Topic:** Quality of Life (QoL)